Neumora Therapeutics Inc

NMRA

Company Profile

  • Business description

    Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.

  • Contact

    260 Arsenal Place
    Suite 1
    WatertownMA02472
    USA

    T: +1 857 760-0900

    https://www.neumoratx.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    63

Stocks News & Analysis

stocks

AI stocks stumble amid growing safety fears

Warnings from Anthropic, OpenAI, and SpaceX are raising questions over the future of the AI buildout.
stocks

ASX miner raises dividend despite earnings miss

Dividend surprise boosts investor confidence.
stocks

Chart of the Week: BHP’s valuation hits historic levels

BHP and peers are trading as if the copper boom is here to stay.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,910.9036.400.41%
CAC 408,186.930.000.00%
DAX 4025,716.71178.960.70%
Dow JONES (US)51,778.04316.140.61%
FTSE 10010,816.14127.671.19%
HKSE24,604.29109.49-0.44%
NASDAQ26,418.30439.871.69%
Nikkei 22564,136.25213.250.33%
NZX 50 Index13,780.9424.350.18%
S&P 5007,637.7685.951.14%
S&P/ASX 2008,732.4035.900.41%
SSE Composite Index3,875.6016.00-0.41%

Market Movers